Skip to content
  • Careers
  • Contact
Pyxis Oncology Logo
  • About
    • Overview
    • Leadership
    • Partners
  • Our Approach
    • ADC Landscape
    • I/O Landscape
  • Portfolio
    • A Novel Pipeline
    • ADCs
    • Our Target Catalog
  • Investors
    • News releases
    • Events & presentations
    • Corporate governance
      • Governance Overview
      • Board of Directors
      • Management Team
      • Committee composition
    • Financial Information
      • SEC filings
    • Stock Information
      • Stock quote & chart
    • SHAREHOLDER SERVICES
      • Investor FAQs
      • Email alerts
      • RSS feeds
  • Media Coverage
Pyxis Oncology Logo
  • About
    • Overview
    • Leadership
    • Partners
  • Our Approach
    • ADC Landscape
    • I/O Landscape
  • Portfolio
    • A Novel Pipeline
    • ADCs
    • Our Target Catalog
  • Investors
    • News releases
    • Events & presentations
    • Corporate governance
      • Governance Overview
      • Board of Directors
      • Management Team
      • Committee composition
    • Financial Information
      • SEC filings
    • Stock Information
      • Stock quote & chart
    • SHAREHOLDER SERVICES
      • Investor FAQs
      • Email alerts
      • RSS feeds
  • Media Coverage
  • Careers
  • Contact

Day: April 27, 2021

ViewPoints Interview: Pyxis Oncology’s Dr. Lara S. Sullivan and Dr. Ronald Herbst Share Insights on the Importance of Series B Funding to Advance their Portfolio

In the News / By walid

Pyxis debuts next-gen cancer ADCs from under Pfizer’s wing

In the News / By walid

Other news to note for April 27, 2021

In the News / By walid

Pyxis unveils ambitions on ADCs

In the News / By walid

Pyxis Oncology Presents Preclinical Data and Details on Antibody-Drug Conjugate Candidates Supporting Therapeutic Potential

Press Release / By Jennifer

— Pyxis Oncology to host webcast with Key Opinion Leaders (KOLs) on April 27, 2021 at 1:00pm ET — CAMBRIDGE, Mass., April 27, 2021 – Pyxis Oncology (“Pyxis” or the “Company”) today announced the targets of its three antibody-drug conjugate (ADC) candidates along with additional details and preclinical data supporting the potential of its ADC …

Pyxis Oncology Presents Preclinical Data and Details on Antibody-Drug Conjugate Candidates Supporting Therapeutic Potential Read More »

35 Cambridgepark Drive
Suite 100-R
Cambridge, MA 02140
(617) 453-3596 | info@pyxisoncology.com

Pyxis Oncology
Twitter Linkedin-in
  • Copyright © 2022 Pyxis Oncology
  • Privacy Policy
  • Accessibility